485 results on '"Kubota, Ryuji"'
Search Results
2. Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor
3. Correction to: Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS‑CoV‑2 3CL Protease Inhibitor
4. A Phase 1 Study of Ensitrelvir Fumaric Acid Tablets Evaluating the Safety, Pharmacokinetics and Food Effect in Healthy Adult Populations
5. HTLV-1-associated myelopathy/tropical spastic paraplegia with sporadic late-onset nemaline myopathy: a case report
6. Evaluation of the Drug–Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults
7. The ridge line of left pulmonary vein isolation from left atrial appendage can subsequently increase the completion rate of the mitral isthmus block line
8. Population pharmacokinetics of duloxetine in Japanese pediatric patients with major depressive disorder
9. Development of a SARS‐CoV‐2 viral dynamic model for patients with COVID‐19 based on the amount of viral RNA and viral titer
10. Comparison of the empirical linear ablation and low voltage area-guided ablation in addition to pulmonary vein isolation in patients with persistent atrial fibrillation: a propensity score-matched analysis
11. Geographic characteristics of HTLV-1 molecular subgroups and genetic substitutions in East Asia: Insights from complete genome sequencing of HTLV-1 strains isolated in Taiwan and Japan
12. Iliopsoas muscle weakness as a key diagnostic marker in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)
13. Efficacy of L-arginine in patients with HTLV-1-associated neurological disease
14. Identification and tracking of pathological T cell clones in virus-associated neurologic disease
15. 530. Population Pharmacokinetic Analysis of Ensitrelvir, an Inhibitor of 3C-like (3CL) Protease of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) for patients with SARS-Cov-2 Infection
16. Performance evaluation of Espline HTLV-I/II, a newly developed rapid immunochromatographic antibody test for different diagnostic situations
17. VISUAL EVALUATION OF CORONARY CT IMAGES USING LATEST MOTION ARTIFACT CORRECTION TECHNIQUE
18. Human T-lymphotropic virus type 1 (HTLV-1) and cellular immune response in HTLV-1-associated myelopathy/tropical spastic paraparesis
19. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects
20. Pharmacokinetics, safety, and tolerability of single and multiple doses of zuranolone in Japanese and White healthy subjects: A phase 1 clinical trial
21. Evaluation of drug‐drug interactions of ensitrelvir, a SARS‐CoV‐2 3CL protease inhibitor, with transporter substrates based on in vitro and a clinical study
22. Identification and tracking of HTLV-1–infected T cell clones in virus-associated neurologic disease
23. Establishment of a novel diagnostic test algorithm for human T-cell leukemia virus type 1 infection with line immunoassay replacement of western blotting: a collaborative study for performance evaluation of diagnostic assays in Japan
24. Direct Visualization of Antigen-Specific T Cells: HTLV-1 Tax11-19-Specific CD8 + T Cells are Activated in Peripheral Blood and Accumulate in Cerebrospinal Fluid from HAM/TSP Patients
25. Anti-ganglionic acetylcholine receptor antibodies in functional neurological symptom disorder/conversion disorder
26. Efficacy of l ‐Arginine treatment in patients with HTLV‐1‐associated neurological disease
27. 1131. Evaluation of drug-drug interaction potential of ensitrelvir for CYP3A by clinical studies and physiologically-based pharmacokinetic model
28. 1136. No Change of Pharmacokinetics of Metformin by Concomitant Use of Ensitrelvir
29. Evaluation of Drug‐Drug Interactions of Ensitrelvir, a SARS‐CoV‐2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
30. Population Pharmacokinetics and Exposure-Response Relationships of Naldemedine
31. Population pharmacokinetics of doripenem in Japanese subjects and Monte-Carlo simulation for patients with renal impairment
32. Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults
33. Seroprevalence of anti-ganglionic acetylcholine receptor antibodies in patients with functional neurological symptom disorder/conversion disorder
34. The ridge line of left pulmonary vein isolation from left atrial appendage can subsequently increase the completion rate of the mitral isthmus block line
35. Establishment of powder dustiness evaluation method by dustmeter with small amount of pharmaceutical ingredients
36. Iliopsoas Muscle Weakness as a Key Diagnostic Marker in HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP).
37. Additional file 1 of Comparison of the empirical linear ablation and low voltage area-guided ablation in addition to pulmonary vein isolation in patients with persistent atrial fibrillation: a propensity score-matched analysis
38. Decrease of aquaporin‐4 and excitatory amino acid transporter‐2 indicate astrocyte dysfunction for pathogenesis of cortical degeneration in HIV‐associated neurocognitive disorders
39. Efficacy of l‐Arginine treatment in patients with HTLV‐1‐associated neurological disease.
40. High Prevalence of HTLV-1 Carriers Among the Elderly Population in Kagoshima, a Highly Endemic Area in Japan
41. Reduced Tim-3 Expression on Human T-lymphotropic Virus Type I (HTLV-I) Tax-specific Cytotoxic T Lymphocytes in HTLV-I Infection
42. Development of Dynamic Human Reliability Analysis Method Incorporating Human-Machine Interaction
43. Ex Vivo Analysis of Human T Lymphotropic Virus Type 1-Specific CD4⁺ Cells by Use of a Major Histocompatibility Complex Class II Tetramer Composed of a Neurological Disease-Susceptibility Allele and Its Immunodominant Peptide
44. Decreased Human T Lymphotropic Virus Type I (HTLV-I) Provirus Load and Alteration in T Cell Phenotype after Interferon-α Therapy for HTLV-I Associated Myelopathy/Tropical Spastic Paraparesis
45. Increased Activated Human T Cell Lymphotropic Virus Type I (HTLV-I) Tax11-19—Specific Memory and Effector CD8⁺ Cells in Patients with HTLV-I—Associated Myelopathy/Tropical Spastic Paraparesis: Correlation with HTLV-I Provirus Load
46. Severe loss of invariant NKT cells exhibiting anti–HTLV-1 activity in patients with HTLV-1–associated disorders
47. Visualization of HTLV-1–Specific Cytotoxic T Lymphocytes in the Spinal Cords of Patients With HTLV-1–Associated Myelopathy/Tropical Spastic Paraparesis
48. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy
49. Anti-Human T-Cell Leukemia Virus Type 1 (HTLV-1) Antibody Assays in Cerebrospinal Fluid for the Diagnosis of HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis
50. Reduced Foxp3 expression with increased cytomegalovirus-specific CTL in HTLV-I-associated myelopathy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.